IL2 and neoplasm: Treatment with NK-activating cytokines, IL-12 and IL-18, or with an IL-2 mutant (H9 “superkine”) increased survival of MHC-I-deficient tumor-bearing mice, accompanied by restoration of effector functions of MHC-I-deficient tumor-infiltrating NK cells (109).